|Articles|January 15, 2007
IND for iCo
iCo Therapeutics, an Isis Pharmaceuticals licensee, has filed an Investigational New Drug (IND) application with the FDA for iCo-007.
Advertisement
iCo Therapeutics, an Isis Pharmaceuticals licensee, has filed an Investigational New Drug (IND) application with the FDA for iCo-007.
iCo-007, for the treatment of eye diseases such as age-related macular degeneration and diabetic retinopathy, is a second generation drug that inhibits the production of c-Raf kinase, an enzyme associated with the development of new blood vessels in the eye.
Isis will receive a milestone payment from iCo based on the IND filing.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retinal imaging as a window into atrial fibrillation
2
The Wills Retina Report: Mapping gene therapy for wet AMD with Carl D. Regillo, MD, and Allen C. Ho, MD
3
Think outside the cone: Applying the Gulani Keratoconus Classification
4













